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Background: Colorectal cancer (CRC) is a major cause of mortality and morbidity. The impact of inflammatory biomarkers
(C-reactive protein etc.) on CRC is increasingly studied including systemic neutrophil-to-lymphocyte ratio (NLR) as they seem to
predict outcome.
Methods: All patients who underwent curative resection for CRC from 2000 to 2004 at Leeds Teaching Hospitals NHS Trust had
pre-operative NLR calculated. Demographic, histopathological and survival data were collected. Tissue microarrays were created
and stained to determine the mismatch repair (MMR) protein status of each tumour. Local lymphocytic response to the tumour
was assessed and graded.
Results: About 358 patients were eligible. Of these 88 had an NLRX5, which predicted lower overall survival and greater disease
recurrence. A high NLR is associated with higher pT- and pN-stage and a greater incidence of extramural venous invasion. MMR
protein status was not associated with NLR. A pronounced lymphocytic reaction at the invasive margin (IM) indicated a better
prognosis and was associated with a lower NLR.
Conclusion: Neutrophil-to-lymphocyte ratio predicts disease-free and overall survival and is associated with a more aggressive
tumour phenotype. The lymphocytic response to tumour at the IM is associated with NLR however dMMR is not. Neutrophil-to-
lymphocyte ratio is a cheap, easy-to-access test that predicts outcome in CRC.
Colorectal cancer (CRC) is the second most common cause of
cancer death in Western Europe and North America. In the UK in
2010, there were 40 695 newly diagnosed CRCs and 15 708 CRC-
related deaths (CRUK, 2010). Advances in surgical technique,
screening and adjuvant oncological therapies have improved
outcomes but it remains a significant cause of mortality
(Martling et al, 2000; Gill et al, 2004). Adjuvant therapies, while
improving survival in certain groups of patients, cause significant
morbidity and it is therefore vital to identify prognostic factors that
indicate which patients would benefit from this type of treatment.
Traditionally, prognosis in CRC is predicted by histopathological
parameters, including staging criteria such as Dukes’ or TNM
staging (Wood, 1971; Deans et al, 1994). Other factors such as
circumferential resection margin involvement, depth of extramural
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invasion and extramural venous invasion (EMVI) are also
important (Courtney et al, 2009). More recently, increasing
attention has been paid to genetic and epigenetic factors and their
influence on outcome. The presence of microsatellite instability has
been shown to be associated with better prognosis (Gryfe et al,
2000; Hutchins et al, 2011). The identification of specific mutations
can determine prognosis (Hutchins et al, 2011) and response to
treatment, such as RAS mutations predicting a poor response to
cetuximab therapy (Lievre et al, 2006).
The role of the immune system in cancer pathogenesis has been
given an increasingly prominent role. There is a link between
inflammation and outcome in a number of solid tumours (Nozoe
et al, 2001; McKeown et al, 2004; Hilmy et al, 2005; Jamieson et al,
2005; Gerhardt et al, 2006; Lamb et al, 2008). The relationship
between the various inflammatory factors in the tumour micro-
environment and tumour growth, invasion and metastasis has been
explored (Balkwill and Mantovani, 2001; Coussens and Werb,
2002; de Visser et al, 2006; Hanahan and Weinberg, 2011). Cancer
cells generate an immune response in the host. The strength and
type of this response may have an impact on disease progression.
A number of studies have examined the systemic inflammatory
response to tumour and its impact on prognosis. Elevated
C-reactive protein (CRP), produced as part of the acute-phase
response, has been associated with poor outcome in multiple solid
tumours including CRC (McMillan et al, 2003; Wong et al, 2007).
During an acute inflammatory response the ratio of different
leucocyte subsets is altered. There is a neutrophilia often
accompanied by a relative lymphocytopenia (Zahorec, 2001).
Therefore a simple measure of systemic inflammation can be
generated by calculating the neutrophil-to-lymphocyte ratio
(NLR). In 2005 an association was demonstrated between NLR
and outcome in CRC but this was not significant on multivariate
analysis (Walsh et al, 2005). This marker has already been
demonstrated to be an independent prognostic factor following
resection of CRC liver metastases (Halazun et al, 2008). Since then
multiple studies have indicated that NLR predicts outcome in
a variety of stages in CRC and following chemotherapy (Ding et al,
2010; Chua et al, 2011; Hung et al, 2011; Chiang et al, 2012;
Kaneko et al, 2012; Mallappa et al, 2013; Absenger et al, 2013;
Malietzis et al, 2014). However, none have attempted to examine
the underlying mechanisms.
A morphological sub-type of CRC associated with mismatch
repair (MMR) protein deficiency, as a consequence of microsatellite
instability, has been noted to provoke a strong host response to
tumour in the form of a pronounced lymphocytic infiltrate (Dolcetti
et al, 1999; Guidoboni et al, 2001; Drescher et al, 2009). These
cancers also seem to have a better prognosis compared with other
types of CRC (Popat et al, 2005). The presence of tumour-
infiltrating lymphocytes in CRC has also been shown to confer a
better prognosis (Pages et al, 2005; Galon et al, 2006).
The aim of this study was to examine the relationship between
pre-operative NLR and clinico-pathological features in a cohort of
CRC patients undergoing curative resection and outcome. We also
determined the MMR status and local lymphocytic response to
tumour and its association with NLR.
MATERIALS AND METHODS
Patients who underwent potentially curative resection for CRC
at Leeds Teaching Hospitals NHS Trust between September 2000
and January 2004 were identified. All patients included in the
study had a full blood count (including a white cell differential
count) performed a maximum of 7 days prior to their
surgery. Exclusion criteria included any evidence of colonic
perforation or documented sepsis. Sepsis was defined as
a temperature 438 1C in combination with a positive micro-
biological culture sample within 48 h.
Ethical approval for this project was granted by Leeds (East)
Ethics Committee (reference number: 08/H1306/86).
Data collection. All participants had histopathologically proven
colorectal adenocarcinoma. A variety of data was collected from
the histopathology reports including TNM/Dukes’ staging, evi-
dence of EMVI and of resection margin status.
The white cell count and differential was obtained via the
Siemens Advia 2120 (Siemens, Erlangen, Germany) flow cyt-
ometer. Overall neutrophil count was measured in 109 l 1 (normal
range 2.0–7.5 109 l 1). Overall lymphocyte count was measured
in 109 l 1 (normal range 1.0–4.5 109 l 1). Neutrophil-to-lym-
phocyte ratio was calculated and a predefined value of X5 was
taken to represent an elevated NLR (Walsh et al, 2005).
Survival data. Data regarding patient survival were collected from
the Northern and Yorkshire Cancer Registry and Information
Service (NYCRIS). This was used to calculate the overall patient
survival. Overall survival was defined as the time from date of first
surgery to date of death from any cause. Censor points were last
attendance at hospital or date of death. Data regarding disease
recurrence were collected from radiological, histopathological and
endoscopic records, and disease-free survival was calculated.
Disease-free survival was defined as date of first surgery to date
on which disease recurrence, either local or distant, was first
detected. Follow-up protocol was standardized within the color-
ectal department at Leeds Teaching Hospitals NHS Trust.
Determination of MMR status. Tissue microarrays (TMAs) were
constructed using three individual 0.6mm cores of formalin-fixed
paraffin-embedded tumour tissue for each patient. Sections were
taken from the TMAs and stained for the MMR proteins, hMLH-1
and hMSH-2, using pre-determined immunohistochemical proto-
cols. The glass slides were scanned using an Aperio XT slide
scanner (Aperio Technologies Inc, San Diego, CA, USA) and
visualised using Aperio ImageScope (Aperio Technologies Inc).
Each individual tumour core was scored as positive or negative,
with negative defined as the absence of any staining within tumour
cells. Staining within immune cells was used as an internal positive
control. Cases scored as negative for either marker were taken to be
MMR-deficient cancers. In cores with no tumour tissue, assess-
ment of MMR status was not possible and these were classed as
unknown.
Assessment of peritumoral lymphocytes. Slides were cut from
each of the whole tissue blocks and stained with haematoxylin and
eosin. These were scanned and viewed digitally so that the
lymphocytic response to tumour could be assessed.
The scoring system was based on the study by Klintrup et al
(2005). This assessed the tumour centre and invasive margin (IM).
Invasive margin was defined as the interface between the normal
host tissue and the invading edge of the tumour. At the margin the
deepest point of invasion was chosen. Each area was scored as 1 to
3 where 1 was none or low density (no reaction or a mild patchy
lymphocytic response), 2 moderate density (band-like infiltrate
with some cancer cell destruction) and 3 high density (prominent
inflammatory reaction with a cup-like zone and destruction of
cancer cells). All slides were scored by the author based on the
described parameters. To confirm the consistency of scoring,
a total of 120 tumour specimens from the CRC group were scored
by two independent histopathologists, who were blinded to
outcome (NPW and GGH).
Statistical analysis. Data are presented as mean or median
(range). Comparisons between the means of normally distributed
groups were performed using Student’s t-test. Non-parametric data
was analysed using the w2-test.
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Univariate survival trends were compared using Kaplan–Meier
curves and significant differences determined via the log rank
test. To determine whether variables were independently linked
to prognosis, the Cox proportional hazard model was used.
Significant factors on univariate analysis were entered into
a multivariate model. A P-value o0.05 was considered significant.
All statistical analysis was performed using SPSS version 16 (SPPS
Inc., Chicago, IL, USA).
RESULTS
From the cohort, 400 patients with pre-operative bloods taken
within 1 week prior to surgery were identified. About 42 patients
were excluded due to the presence of bowel perforation or sepsis
preoperatively, leaving 358 patients in the study group. All patients
have follow-up of 44 years therefore patients were censored at
4 years for the survival analysis.
Demographics. The study population comprised of 202 (56.4%)
males and 156 (43.6%) females. The median age was 74 years
(range 32–95). About 261 cases were cancers of the colon and 97
were rectal. Of the colonic cancers, 141 were right sided and 120
were left sided.
Clinico-pathological data. Clinico-pathological data is presented
in Supplementary Table 1. About 38 (10.6%) patients were staged
as Dukes’ A, 163 (45.5%) as Dukes’ B, 119 (33.4%) were Dukes’ C
and 37 (10.5%) were stage D. About 138 (38.5%) demonstrated
evidence of EMVI. About 310 (86.6%) patients had complete R0
resections, while in 37 (10.3%) the resection margin was involved
microscopically (R1). R1 was defined as a margin p1mm clear of
tumour.
Neutrophil-to-lymphocyte ratio. Neutrophil-to-lymphocyte ratio
was calculated for each patient producing two groups: high NLR
(NLRX5) and low NLR (NLRo5). This cut-off was used as
previously cited in the relevant literature (Walsh et al, 2005). The
median age for both groups was 74 years. The distribution of
gender in each group is similar (Table 1). The site of tumour in the
low NLR group was 81.2% colon and 18.8% rectum compared with
89.4% colon and 10.6% rectum in the high NLR group (P¼ 0.186).
Table 1 contains data comparing clinico-pathological factors
within the high and low NLR groups. Median maximum tumour
diameter in the NLR o5 group was 4.0 cm compared with 3.5 cm
in the NLR X5 group (P¼ 0.153). The grade of differentiation in
each group was similar. It is clear from Table 1 that NLR is
associated with a more advanced, aggressive tumour type. The
NLRX5 group tumours are more likely to have a higher pT-stage
(Po0.001) and pN-stage (P¼ 0.014). They are more likely to be
associated with more positive lymph nodes and evidence of EMVI.
The percentage of the NLR X5 group that was stage D/IV was
20.5% compared with 8.6% in the low NLR group.
Patient survival. Overall survival for the entire cohort is
demonstrated (separated by Dukes’ stage) in Supplementary
Figure 1. The difference between the four groups is significant
(Po0.001). When the overall survival for the high NLR group is
compared with the low NLR group the outcomes for those with an
NLR X5 is significantly poorer (Figure 1A). Thirty-day mortality
(3.7 vs 19.3%, Po0.001), 90-day mortality (7.4 vs 24.0%, Po0.001)
and 4-year survival (59.6 vs 27.3%, Po0.001) are significantly
worse in the high NLR group. Disease-free survival also
demonstrated poorer survival in the NLR X5 group (Figure 1B).
Overall survival in the NLRo5 andX5 groups by Dukes’ stage is
shown in Supplementary Figure 2. This indicates that the
prognostic effect of NLR may be independent of Dukes’ stage.
Univariate/multivariate analysis. Univariate analysis for overall
survival was performed on age, gender, NLR and clinico-
pathological factors. The results can be seen in Table 1 with
significant factors including age, NLR, CRP level, number of
positive lymph nodes, EMVI, pT- and pN-stage, and Dukes’ stage.
The hazard ratio (HR) for NLR was 2.62 (95% CI 1.93–3.55,
Po0.001) making it one of the stronger predictors on univariate
analysis. Significant factors (Po0.05) were put through a multi-
variate model and the results are shown in Table 1. The factors that
remained significant were age, NLR and Dukes’ stage C and stage D.
A similar analysis was performed for disease-free survival. On
univariate analysis, NLR, number of positive lymph nodes, EMVI,
complete resection and Dukes’ stage were significant. On multi-
variate analysis, NLR, EMVI and Dukes stage C remained
significant (Supplementary Table 2).
MMR status and NLR
Demographics. The incidence of MMR deficiency compared with
NLR of CRC patients is shown in Table 2. Demographic data
shown in Supplementary Table 3 demonstrates some of the
features associated with MMR-deficient tumours, namely female
gender and right-sided tumours.
Association between MMR status and NLR. The ratios of NLR
o5 and X5 against the presence, or otherwise, of the MMR
proteins are shown in Table 2. There appears to be no association
between the two groups.
Tumour-associated lymphocytes in CRC. The intraclass correla-
tion co-efficient (ICCC) between the author and the observers was
0.70 (GGH) and 0.87 (NPW) at the IM and 0.88 (GGH) and 0.85
(NPW) at the tumour centre. Inter-observer ICCCs 40.7 are
considered acceptable (Streiner and Norman, 1995).
Based on the original grading system (Klintrup et al, 2005),
Kaplan–Meier curves for overall survival were constructed using
the results obtained from the IM (Figure 2A). These demonstrated
a significant difference in patient outcomes for each group with a
more pronounced lymphocytic reaction being associated with a
better prognosis (P¼ 0.004). The same curves were produced for
the lymphocytic reaction seen at the tumour centre but no
significant difference was observed between the groups (Figure 3).
Characteristics of the mild vs pronounced lymphocytic reaction
(at the IM) groups. These characteristics are shown in Table 3.
There was no difference in age or gender between the two groups.
There is a trend towards colonic tumours being more likely to
produce a moderate-to-severe lymphocytic reaction than rectal
tumours but this did not reach statistical significance. A moderate-
to-severe lymphocytic reaction at the IM is associated with MMR
deficiency (P¼ 0.040), decreased incidence of EMVI (P¼ 0.010)
and lower Dukes’ stage (P¼ 0.001). There is a significant
association between raised NLR and a milder degree of
lymphocytic infiltration at the IM with 15.3% of the moderate
and severe lymphocytic response groups having an NLR X5
compared with 29.2% of the mild lymphocytic response group
(P¼ 0.005).
On univariate analysis, grade of lymphocytic reaction at the IM
was a significant prognostic factor (HR 1.75, 95% CI 1.24–2.47,
P¼ 0.001). However, when it is included in the multivariate model
for overall survival in this group it is not significant (Table 4).
Disease-free survival by grade of lymphocytic reaction at the
IM. Disease-free survival for the two lymphocytic response groups
(none/mild vs moderate/severe) was calculated. The survival curves
(Figure 2B) show a clear difference between groups (P¼ 0.010). On
univariate analysis, grade of lymphocytic reaction at the IM was a
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significant prognostic factor (HR 1.87, 95% CI 1.07–3.30, P¼ 0.029).
On multivariate analysis this was not significant (Table 5).
DISCUSSION
This study assessed the impact of NLR on a retrospective series of
CRC patients. The cohort consisted of a variety of patients
presenting at Dukes’ stage A to C (with a small proportion of
patients with stage IV disease and resectable liver metastases).
Histopathological parameters such as the number of positive
lymph nodes and evidence of EMVI were shown to be prognostic.
As expected various staging methods (TNM, Dukes’) also predict
outcome. These data demonstrated that pre-operative NLR
predicted survival. By splitting the cohort into two groups (NLR
o5 and NLR X5) the difference in outcome was illustrated by
survival curves for overall and disease-free survival (Figure 1A and
B). On univariate analysis of overall survival, NLR was shown to be
prognostic (HR 2.62, 95% CI 1.93–3.55, P¼o0.001). Neutrophil-
to-lymphocyte ratio, along with age and Dukes’ stage, remains
significant in a multivariate model. When the high and low NLR
groups are analysed it becomes apparent that NLR is associated
with more advanced, aggressive tumour biology with more lymph
node metastases and EMVI.
To further assess the effect of tumour biology on NLR, we
investigated the role of MMR status. Our MMR-deficient cancers
had typical characteristics of this tumour type: female gender and
right-sided lesions (Lanza et al, 2006). Unlike many series MMR
status did not demonstrate any differences in survival. Mismatch
repair-deficient cancers were associated with a more prominent
peritumoral lymphocytosis. It is thought that the anti-tumoural
effect of T-lymphocytes within the infiltrative population may
account for the better outcomes observed in this group. As a
component of NLR is circulating lymphocytes, we postulated that
the lymphocytic reaction seen in MMR cancers may be associated
with NLR. However, on analysis no correlation between MMR
status and NLR was observed. This may be a type II error and
larger series/meta-analyses would be required to confirm or refute
this hypothesis.
Table 1. Univariate and multivariate analysis for overall survival (covariates included in multivariate model highlighted in bold)
Univariate Multivariate
Covariate N P-value HR 95% CI P-value HR 95% CI
NLR
o5 270 — 1.00 — — 1.00 —
X5 88 o0.001 2.616 1.925–3.553 o0.001 1.819 1.310–2.526
Age (years)
p70 129 — 1.00 — — 1.00 —
470 229 o0.001 2.549 1.799–3.612 o0.001 2.964 2.045–4.297
Gender
M 202 — 1.00 — — — —
F 156 0.920 1.015 0.758–1.360 — — —
CRP (U)
p10 74 — 1.00 — — — —
410 90 0.025 1.640 1.063–2.528 — — —
Total lymph nodes found
0–15 178 — 1.00 — — — —
415 178 0.020 1.419 1.057–1.904 — — —
EMVI
Y 138 — 1.00 — — 1.00 —
N 213 o0.001 2.210 1.641–2.976 0.139 1.294 0.920–1.820
pT-stage
1 11 — 1.00 — — — —
2 32 0.596 0.731 0.229–2.330 — — —
3 212 0.757 1.171 0.430–3.188 — — —
4 98 0.036 2.931 1.070–8.024 — — —
pN-stage
0 203 — 1.00 — — — —
1 88 0.048 1.454 1.002–2.108 — — —
2 65 o0.001 3.712 2.615–5.272 — — —
Complete resection
Y 310 — 1.00 — — — —
N 37 0.130 1.435 0.917–2.246 — — —
Site of tumour
Colon 261 — 1.00 — — — —
Rectum 97 0.161 0.783 0.556–1.102 — — —
Dukes’ stage
A 38 — 1.00 — — 1.00 —
B 163 0.510 1.223 0.672–2.228 0.999 0.999 5.33–1.875
C 119 0.02 2.701 1.430–5.100 0.025 2.097 1.098–4.007
D 37 o0.001 6.776 3.408–13.474 o0.001 6.665 3.241–13.707
Abbreviations: CI¼ confidence interval; CRP¼ c-reactive protein; EMVI¼ extramural vascular invasion; F¼ female; HR¼hazard ratio; M¼male; N¼no; NLR¼ neutrophil-to-lymphocyte ratio;
Y¼ yes.
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We examined the local lymphocytic reaction to tumour. We found
that when absent/mild, moderate and severe lymphocytosis at the IM
was compared the patient outcomes differed markedly with the
moderate and severe groups having a significant survival advantage. It
was demonstrated that a moderate-to-severe lymphocytic infiltrate at
the IM was associated with a less advanced Dukes’ stage, less EMVI
and MMR-deficient cancers. The lymphocytic reaction also correlated
with NLR in that a moderate-to-severe reaction was significantly less
likely to exhibit a raised NLR (P¼ 0.005).
Our study comprises a retrospective cohort of consecutive
patients treated in Leeds between 2000 and 2004. There are
limitations to the study. The small size of the cohort makes it
difficult to draw comprehensive conclusions. The heterogeneous
nature of the data (variation in patient physiology, treatment and
tumour biology) makes comparisons between groups difficult and
increases the risk of individual factors skewing the data. We were
unable to separate elective and emergency resections. We attempt to
correct for this by identifying and excluding patients with evidence
of sepsis or bowel perforation. However, emergency presentations
have worse outcomes, particularly in the early post-operative period
(Ueberrueck et al, 2013). This may bias our results and may
contribute to the early mortality seen in the NLR high group.
The relationship between NLR and cancer has been explored
elsewhere in the literature. Cho et al (2009) demonstrated that not
only was NLR more likely to be elevated in patients with epithelial
ovarian cancer, compared with patients with benign conditions
and normal controls, but that the pre-treatment value predicted
patient survival (Cho et al, 2009). Similar findings have been seen
in non-small cell lung cancer (Sarraf et al, 2009). In CRC Walsh
et al (2005) examined a cohort of 230 CRC patients over a 2-year
period. They found that pre-operative NLR 45 correlated with
overall and cancer-specific survival on univariate analysis. How-
ever, on multivariate analysis it was not independent of Dukes’
stage (Walsh et al, 2005). NLR also predicts outcome in stage II
(Ding et al, 2010; Hung et al, 2011) and stages I–III CRC (Chiang
et al, 2012; Mallappa et al, 2013; Malietzis et al, 2014). It is
prognostic in metastatic CRC patients and those with metastatic
disease undergoing palliative chemotherapy (Chua et al, 2011;
Kaneko et al, 2012). This suggests that NLR is an indicator of
prognosis in CRC and, when used with more established
predictors, can identify patients who may benefit from adjuvant
treatment or more frequent surveillance.
There are a number of mechanisms by which the prognostic
effect of NLR may be produced. It is thought to be a simple
measure of the systemic inflammatory response and an elevated
value may represent tumour-generated inflammation (O’Mahony
et al, 1984). If pro-inflammatory cytokines, such as TNF-a and IL’s
1, 6 and 8, are upregulated as part of an inflammatory response this
can have important effects on tumour growth and progression.
These inflammatory mediators activate intracellular pathways,
such as those mediated by NF-kB, modulate cellular proliferation
and angiogenesis and may have a profound effect on tumour
growth and invasion.
Lymphocytopenia is an important component of a high NLR
and its value may be indicative of the type and degree of
lymphocytic response to tumour. A low level of blood-borne
lymphocytes may reflect a muted or absent lymphocytic response
to tumour. Tumours with an increased population of intrae-
pithelial T-lymphocytes, particularly the CD8þ cytotoxic
phenotype, have better outcomes (Dolcetti et al, 1999). The
NLR may reflect the type of T-cell response. Evidence suggests
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Figure 1. Kaplan–Meier curves comparing survival for NLRo5 vs
NLRX5. (A) Overall survival (n¼ 358, Po0.001, HR 2.616, 95% CI
1.925–3.553). (B) Disease-free survival (n¼317, Po0.001, HR 2.547,
95% CI 1.521–4.265). NLR¼ neutrophil-to-lymphocyte ratio.
Table 2. MMR protein deficiency/proficiency in the NLR
groups
NLR
Total o5 X5 P-valuea
hMLH-1
Negative 45 (12.6%) 37 (13.7%) 8 (9.1%) 0.247
Positive 291 (81.3%) 216 (80.0%) 75 (85.2%) —
Unknown 22 (6.1%) 17 (6.3%) 5 (5.7%) —
hMSH-2
Negative 12 (3.4%) 8 (3.0%) 4 (4.5%) 0.489
Positive 326 (91.1%) 246 (91.1%) 80 (90.9%) —
Unknown 20 (5.6%) 16 (5.9%) 4 (4.5%) —
Final MMR status
Deficient 55 (15.4%) 44 (16.3%) 11 (12.5%) 0.356
Proficient 286 (79.9%) 212 (78.5%) 74 (84.1%) —
Unknown 17 (4.7%) 14 (5.2%) 3 (3.4%)
Abbreviations: NLR¼ neutrophil-to-lymphocyte ratio; MMR¼mismatch repair.
aw2-test.
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that even when lymphocytic aggregates are present in a tumour
their immune responsiveness is often blunted by cytokines within
the microenvironment (Zippelius et al, 2004). Cells are often
polarised away from the anti-tumour Th-1 phenotype towards a
more immunosuppressive Th-2 type. This blunts the anti-tumour
response and creates a milieu in which tumour cell populations
can develop unimpeded (Balkwill and Mantovani, 2001).
Cytokines associated with Th-1 polarisation, such as IFN-g or
IL-12, and associated pro-inflammatory cytokines, such as IL-2,
may also have a role.
As well as being implicated in the inflammatory response and its
associated cancer promoting pathways, NLR may also offer an
indication of the physiological condition of the patient. In more
advanced CRC causing large bowel obstruction, a neutrophilia
would be generated. Such patients may have a greater mortality
rate than patients without such problems. This may contribute to
the impact of NLR on overall survival; however, an elevated NLR is
also seen in patients with early stage cancer.
Like others we have demonstrated that the pre-operative
systemic NLR predicts both overall survival and disease recurrence
following surgery for CRC. However, we have gone onto
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Figure 2. Kaplan–Meier curves showing survival by grade of
lymphocytic reaction at the invasive margin. (A) Overall survival
(n¼344, P¼0.004, HR 1.751, 95% CI 1.241–2.469). (B) Disease-free
survival (n¼310, P¼0.010, HR 1.873, 95% CI 1.065–3.295).
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Figure 3. Kaplan–Meier curves showing overall survival by grade of
lymphocytic reaction at the tumour centre (n¼344, P¼ 0.380).
Table 3. Data by grade of lymphocytic reaction at the invasive
margin
Total
None/low
density
(Group 1)
Moderate/
severe density
(Groups 2 and 3) P-value
N 351 240 (68.4%) 111 (31.6%) —
Median
age (years)
73 73 73 0.946a
Gender
Male 200 (57.0%) 142 (59.2%) 58 (52.3%) 0.224b
Female 151 (43.0%) 98 (40.8%) 53 (47.7%) —
Site of tumour
Colon 256 (72.9%) 168 (70.0%) 88 (79.3%) 0.069b
Rectum 95 (27.1%) 72 (30.0%) 23 (20.7%) —
Dukes’ stage
A 37 (10.5%) 17 (7.1%) 20 (18.0%) 0.001b
B 157 (44.7%) 100 (41.7%) 57 (51.4%) —
C 119 (33.9%) 91 (37.9%) 28 (25.2%) —
D 37 (10.5%) 32 (13.3%) 5 (4.5%) —
EMVI
Yes 137 (39.0%) 105 (43.8%) 32 (28.8%) 0.01b
No 208 (61.0%) 132 (56.2%) 76 (71.2%) —
MMR status
Deficient 55 (15.7%) 31 (12.9%) 24 (21.6%) 0.04b
Proficient 281 (84.3%) 198 (87.1%) 83 (78.6%) —
NLR
o5 264 (%) 170 (70.8%) 94 (84.7%) 0.005b
X5 87 (%) 70 (29.2%) 17 (15.3%)
Abbreviations: EMVI¼extramural vascular invasion; MMR¼mismatch repair; NLR¼
neutrophil-to-lymphocyte ratio.
aMann–Whitney U-test.
bw2-test.
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demonstrate a strong association of NLR with histopathology
features of the local immune response rather than MMR status and
the frequency of nodal involvement and EMVI. While the
immunological mechanism for this phenomenon remains unclear,
this represents a cheap, easily accessible test that can provide
valuable prognostic information prior to surgical intervention.
Further work is needed to investigate the immunological basis for
these observations, as well as whether they affect the developing
immunotherapeutic approaches in such patients.
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